Savella Tablets

Description

Drug name: Savella

Generic name: Milnacipran

Drug class: Serotonin-norepinephrine reuptake inhibitor (SNRI)

Manufacturer: Forest Laboratories, Inc.

FDA approval date: January 14, 2009

Dosage forms: 12.5 mg, 25 mg, 50 mg tablets

Indications: Management of fibromyalgia

Administration: Orally, once daily with or without food

Common side effects:

• Nausea
• Headache
• Constipation
• Dizziness
• Insomnia
• Hot flush

Serious side effects:

• Seizures
• Suicidal thoughts or behaviors
• Increased blood pressure
• Liver problems
• Allergic reactions

Contraindications:

• Hypersensitivity to milnacipran or any component of the formulation
• Uncontrolled narrow-angle glaucoma
• End-stage renal disease (ESRD)
• Severe hepatic impairment

Drug interactions:

• Monoamine oxidase inhibitors (MAOIs)
• Triptans
• Serotonin receptor agonists
• Other SNRIs
• Tricyclic antidepressants (TCAs)
• St. John’s wort
• Linezolid
• Lithium

Pregnancy category: C

Breastfeeding category: Unknown

Approval status: Prescription only

Legal status: Schedule IV (US)